NCT07417267Enrolling by invitation
Clean Air for Rare MUcociliary Clearance dIsorders
Clean Air for Rare MUcociliary Clearance dIsorders (CARMUCI)
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
The goal of this clinical trial is to learn whether using a high efficiency particulate air (HEPA) air purifier can improve respiratory health in children and adults with Cystic Fibrosis (CF) or Primary Ciliary Dyskinesia (PCD). The main questions it aims to answer are: Can using a HEPA air purifier at home reduce respiratory symptoms in people with CF or PCD? Can it improve lung function and overall health? Researchers will compare participants' health outcomes before and after the use of the HEPA air purifier to see if cleaner indoor air makes a measurable difference. Participants will: Visit the clinic for baseline health assessments (such as lung function and symptom questionnaires). Have two HEPA air purifiers installed in their home. One device will be placed in the main living area and one in the bedroom. Undergo exposure assessments during home visits to measure indoor air quality.
- Status (registry)
- Enrolling by invitation
- Study type
- Interventional
- Enrollment
- 62 (estimated)
- First submitted
- 30 Dec 2025
- Start date
- 1 May 2025
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- University of Cyprus
- Diseases
- Cystic fibrosis
- NCT number
- NCT07417267
What you commit to
- Study type: Interventional
- Planned participants: 62
- From 1 May 2025 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hospitalization for any condition during the study period or lack of internet access, which is required for continuous data transmission
Other
- Active smoking
Who the study is looking for
- Age ≥6 years
- Physician-confirmed diagnosis of CF or PCD, based on internationally accepted criteria. PCD diagnosis will be based on either a) a positive genetic test (bi-allelic disease-causing mutations) or b) TEM class 1 defect, as defined by the European Respiratory Society and American Thoracic Society guidelines for the diagnosis of PCD. CF diagnosis will be based on the diagnostic criteria of the European Cystic Fibrosis Society Patient Registry including: (a) two sweat chloride test values of at least 60 mmol/L, or (b) one sweat chloride test value of at least 60 mmol/L and two disease-causing CFTR mutations, or (c) typical CF features at clinical presentation and two disease-causing CFTR mutations if sweat chloride test value was less than 60 mmol/L or not reported.
- Residing in a main household in Cyprus for at least 5 days per week during the study period.
- Willingness and ability to provide informed consent (or approval with guardian consent for minors).
Age in the registry: 6 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical School, University of Cyprus Coordinator of this site? Confirm its status | Nicosia | Cyprus | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.